Blackstone Inc’s PTC Therapeutics PTCT Stock Holding History

Blackstone Inc’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$706K	Buy	+10,367	New	+$734K	﹤0.01%	268
2025 Q1	–	Sell	-1,059,574	Closed	-$47.8M	–	186
2024 Q4	$47.8M	Sell	1,059,574 -35,716	-3%	-$1.53M	0.22%	45
2024 Q3	$40.6M	Hold	1,095,290	–	–	0.18%	44
2024 Q2	$33.5M	Hold	1,095,290	–	–	0.14%	49
2024 Q1	$31.9M	Hold	1,095,290	–	–	0.13%	54
2023 Q4	$30.2M	Hold	1,095,290	–	–	0.14%	52
2023 Q3	$24.5M	Hold	1,095,290	–	–	0.1%	58
2023 Q2	$44.5M	Hold	1,095,290	–	–	0.19%	47
2023 Q1	$53.1M	Hold	1,095,290	–	–	0.22%	40
2022 Q4	$41.8M	Buy	+1,095,290	New	+$45.5M	0.16%	43

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Blackstone Inc's PTCT Position: Q1 2026 in Review

Blackstone Inc opened a new position in PTC Therapeutics (PTCT) in Q1 2026: 10,367 shares worth $706K. The stake represents ﹤0.01% of the portfolio and ranks #268 among its holdings. This is a return to the name: Blackstone Inc previously reported a position in PTCT as recently as Q4 2024.

Blackstone Inc first reported a position in PTCT in Q4 2022 and has held it in 10 quarters since. The position peaked at $53.1M in Q1 2023. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

Blackstone Inc held 10,367 shares of PTC Therapeutics worth $706K as of Q1 2026.
PTC Therapeutics was a new Blackstone Inc position in Q1 2026.
PTC Therapeutics made up ﹤0.01% of Blackstone Inc's portfolio in Q1 2026, its #268 holding.
Blackstone Inc first reported a position in PTC Therapeutics in Q4 2022 and has held it in 10 quarters since.
Blackstone Inc's PTC Therapeutics position peaked at $53.1M in Q1 2023.
349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Blackstone Inc's 13F filing for Q1 2026, filed 15 May 2026.